(Q37793666)

23 August 2017

title

Review article: eplerenone: an underused medication? (English)

1 reference

23 August 2017

Review Article: Eplerenone: An Underused Medication? (English)

1 reference

https://api.crossref.org/works/10.1177/1074248410371946

21 July 2024

1 reference

Mohammad Abuannadi

1

1 reference

23 August 2017

James H. O'Keefe

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20876342

21 July 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20876342

21 July 2024

publication date

27 September 2010

1 reference

full work available at URL

23 August 2017

http://journals.sagepub.com/doi/pdf/10.1177/1074248410371946

1 reference

https://api.crossref.org/works/10.1177/1074248410371946

Journal of Cardiovascular Pharmacology and Therapeutics

21 July 2024

published in

1 reference

23 August 2017

volume

15

1 reference

23 August 2017

issue

4

1 reference

23 August 2017

page(s)

318-325

1 reference

Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction

23 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F1074248410371946

Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248410371946

Eplerenone: cardiovascular protection

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248410371946

Pharmacokinetics and pharmacodynamics of mineralocorticoid blocking agents and their effects on potassium homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248410371946

Prediction of in vivo drug interactions with eplerenone in man from in vitro metabolic inhibition data

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248410371946

Involvement of CYP3A in the metabolism of eplerenone in humans and dogs: differential metabolism by CYP3A4 and CYP3A5.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248410371946

The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248410371946

A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248410371946

A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248410371946

Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248410371946

Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248410371946

Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248410371946

"Escape" of aldosterone production in patients with left ventricular dysfunction treated with an angiotensin converting enzyme inhibitor: implications for therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248410371946

The effects of eplerenone on length of stay and total days of heart failure hospitalization after myocardial infarction in patients with left ventricular systolic dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248410371946

Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248410371946

Timing of eplerenone initiation and outcomes in patients with heart failure after acute myocardial infarction complicated by left ventricular systolic dysfunction: insights from the EPHESUS trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248410371946

Cost-effectiveness of eplerenone compared with placebo in patients with myocardial infarction complicated by left ventricular dysfunction and heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248410371946

Cost effectiveness of eplerenone in patients with heart failure after acute myocardial infarction who were taking both ACE inhibitors and beta-blockers: subanalysis of the EPHESUS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248410371946

Immediate mineralocorticoid receptor blockade improves myocardial infarct healing by modulation of the inflammatory response

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248410371946

Effects of eplerenone on transcriptional factors and mRNA expression related to cardiac remodelling after myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248410371946

Cardioprotective effects of eplerenone in the rat heart: interaction with locally synthesized or blood-derived aldosterone?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248410371946

Mapping preconditioning's signaling pathways: an engineering approach.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248410371946

Extracellular cardiac matrix biomarkers in patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure: insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Stu

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248410371946

Left ventricular remodeling after acute myocardial infarction: does eplerenone have an effect?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248410371946

Natural history of markers of collagen turnover in patients with early diastolic dysfunction and impact of eplerenone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248410371946

Eplerenone, but not steroid withdrawal, reverses cardiac fibrosis in deoxycorticosterone/salt-treated rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248410371946

Aldosterone induces a vascular inflammatory phenotype in the rat heart

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248410371946

Mineralocorticoid receptor antagonism attenuates cardiac hypertrophy and failure in low-aldosterone hypertensive rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248410371946

Mineralocorticoid receptor inhibition ameliorates the transition to myocardial failure and decreases oxidative stress and inflammation in mice with chronic pressure overload

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248410371946

Screening, treatment, and control of hypertension in US private physician offices, 2003-2004

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248410371946

Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248410371946

Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248410371946

Hydrochlorothiazide versus chlorthalidone: evidence supporting their interchangeability

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248410371946

Clinical effects of eplerenone, a selective aldosterone blocker, in Japanese patients with essential hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248410371946

Assessment of the novel selective aldosterone blocker eplerenone using ambulatory and clinical blood pressure in patients with systemic hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248410371946

Efficacy of eplerenone added to renin-angiotensin blockade in hypertensive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248410371946

Efficacy of eplerenone versus enalapril as monotherapy in systemic hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248410371946

Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248410371946

Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248410371946

Effects of eplerenone versus losartan in patients with low-renin hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248410371946

Symptoms and the distress they cause: comparison of an aldosterone antagonist and a calcium channel blocking agent in patients with systolic hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248410371946

Renoprotective effects of mineralocorticoid receptor blockade in heminephrectomized (pro)renin receptor transgenic rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248410371946

Mineralocorticoid receptor blockade enhances the antiproteinuric effect of an angiotensin II blocker through inhibiting podocyte injury in type 2 diabetic rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248410371946

Eplerenone inhibits atherosclerosis in nonhuman primates

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248410371946

Selective mineralocorticoid receptor blocker eplerenone reduces resistance artery stiffness in hypertensive patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248410371946

Aldosterone and the vascular system

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248410371946

A randomized trial of the aldosterone-receptor antagonist eplerenone in asymptomatic moderate-severe aortic stenosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248410371946

Serum potassium and clinical outcomes in the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248410371946

Life-threatening hyperkalemia during combined therapy with angiotensin-converting enzyme inhibitors and spironolactone: an analysis of 25 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248410371946

Long-term safety and efficacy of the selective aldosterone blocker eplerenone in patients with essential hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248410371946

Efficacy and tolerance of spironolactone in essential hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248410371946

Short- and long-term neurohormonal activation following acute myocardial infarction

21 January 2018

10

1 reference

https://api.crossref.org/works/10.1177/1074248410371946

Evidence of a partial escape of renin-angiotensin-aldosterone blockade in patients with acute myocardial infarction treated with ACE inhibitors

21 July 2024

18

1 reference

https://api.crossref.org/works/10.1177/1074248410371946

Long-term mineralocorticoid receptor blockade reduces fibrosis and improves cardiac performance and coronary hemodynamics in elderly SHR

21 July 2024

34

1 reference

https://api.crossref.org/works/10.1177/1074248410371946

Mortality after 10 1/2 years for hypertensive participants in the Multiple Risk Factor Intervention Trial

21 July 2024

40

1 reference

https://api.crossref.org/works/10.1177/1074248410371946

Beneficial effects of eplerenone versus hydrochlorothiazide on coronary circulatory function in patients with diabetes mellitus

21 July 2024

56

1 reference

https://api.crossref.org/works/10.1177/1074248410371946

21 July 2024

Identifiers

1 reference

23 August 2017

1 reference